Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
General Outlook
In simple terms, Tricida, Inc. has 55.114 M shares that people are buying and selling right now.
Return on Investments
The company's asset efficiency, represented by a robust -0.957% return, is a testament to Tricida, Inc.'s adeptness in optimizing resource deployment. Tricida, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.798%. Furthermore, the proficiency of Tricida, Inc. in capital utilization is underscored by a remarkable -1.014% return on capital employed.
Stock Prices
Tricida, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.25, while its low point bottomed out at $0.23. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Tricida, Inc.'s stock market.
